Brief

Zhenbaodao Pharmaceutical's subsidiary has secured the exclusive sales agency rights in China for TRS005, an innovative biological drug developed by Zhejiang Teruis. This drug, designed to treat relapsed or refractory non-Hodgkin lymphoma, has already received a breakthrough therapy designation and is undergoing a crucial Phase II clinical trial. The agreement is set to run from 2027 to 2036, with specific sales commissions and targets to be determined post-approval, though revenue generation before product approval remains uncertain. AI

Jiaoda Sinno plans to acquire a 60.28% stake in Beijing Xintongchuanglian Technology, a company specializing in railway communication products. This acquisition aims to strengthen Jiaoda Sinno's market position in the railway sector and diversify its product offerings. The company will also raise additional capital through a private placement to no more than 35 investors. Separately, Zhenbaodao's subsidiary has entered into a strategic agreement with Zhejiang Teres to become the sales agent for their innovative biologic drug TRS005 in China, which is intended for treating certain types of lymphoma. AI